Pacritinib is a novel “multi-target” agent, developed for myelofibrosis, which inhibits JAK2/FLT3/IL-1 receptor associated kinase (IRAK1)/colony stimulating factor 1 receptor (CFS1R). Here, FLT3 is linked to myelofibrosis.